Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07579221
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The goal of this clinical research study is to find a safe and tolerable dose of navlimetostat in combination with pumitamig that can be given to patients with MTAP-deficient advanced non-small cell lung cancer (NSCLC). The effectiveness of the study drugs will also be studied.

Key Dates

Start date
Nov 30, 2026
Status verified
Jun 2026
Primary completion
Aug 1, 2029
Completion
Aug 1, 2031

Study Design

Enrollment
17 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Phase 1 Safety Lead-In: Treatment with Navlimetostat + Pumitamig
    Participants will receive treatment with the combination of navlimetostat, administered orally once daily (QD) combined with pumitamig, administered intravenously (IV) every 3 weeks (Q3W) in 21- day cycles until disease progression or treatment intolerance.
  • Experimental: Phase 2 Efficacy Evaluation: Treatment with Navlimetostat + Pumitamig
    Participants will receive treatment with the combination of navlimetostat, administered orally once daily (QD) combined with pumitamig, administered intravenously (IV) every 3 weeks (Q3W) in 21- day cycles until disease progression or treatment intolerance.

Primary Outcome Measure

Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UT MD AndersonHoustonTexas77090
Natalie Vokes, MD
Natalie Vokes, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
UT MD Anderson· Houston, TX

Related Studies